Action Steps to Address Inequities in Cancer Care Access, Treatment, and Outcomes in Your Community


Scott Cook, PhD
Leading Care, Payment, and Systems Transformation, Robert Wood Johnson Foundation
Quality Improvement and Care Transformation Strategist, Department of Diversity, Equity, and Inclusion
University of Chicago Medicine and Biological Sciences, Chicago, IL
Scott Cook, PhD

Dr. Cook is a clinical psychologist experienced in providing integrated behavioral health services in primary care clinics and hospitals serving diverse and resilient urban and rural populations. He received his masters and doctoral degrees from the University of Missouri – Columbia. He completed his internship at Cook County Stroger Hospital, the major public hospital in Chicago.

Scott worked for eight years in leadership and clinical roles in research, behavioral health, youth services, and community services at Howard Brown Health, serving the diverse LGBTQIA+ communities of Chicago. He was the deputy director of Finding Answers, a national program of the Robert Wood Johnson Foundation, a faculty member for the Taking Action on Overuse Fellowship program, and serves on the FamiliesUSA Health Equity Task Force.

He works at UChicago Medicine in quality improvement and organizational development roles to eliminate health inequities. He also partners with his teammates to advance the organization’s equity, diversity, and inclusion innovation agenda. He co-directs the Advancing Health Equity: Leading Care, Payment, and Systems Transformation program of the Robert Wood Johnson Foundation, based at the University of Chicago. Dr. Cook is a founding co-chair of the University of Chicago LGBT+ Resource Group, a recipient of the University’s Diversity Leadership Award and has volunteered in multiple capacities in community organizations, including serving eight years in various leadership positions as a board member of TPAN.

Aung Naing, MD, FACP
Professor, Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center, Houston, TX
Editor-in-Chief, Journal of Immunotherapy and Precision Oncology
Aung Naing, MD, FACP

Aung Naing, MD, FACP, is Professor and Lead of the Immunotherapy Working Group in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. Dr. Naing has extensive experience developing first-in-human, early-phase clinical trials including several immunotherapy-based trials.

Dr. Naing’s research focuses on clinical translation of basic immunobiology and is aimed at identifying biomarkers to predict response, resistance, and immune-related adverse events associated with immunotherapies. He has authored and co-authored more than 270 original research articles in high-impact journals such as Cell, Lancet Oncology, Cancer Cell, and Journal of Clinical Oncology. Recently, he edited the fourth edition of the book entitled “Immunotherapy” published by Springer International Publishing AG. He also serves as the course director for a Tumor Immunology course at the University of Texas Graduate School of Biomedical Sciences.

As an expert in developmental therapeutics, Dr. Naing has served as a discussant for poster presentations in ASCO, AACR and SITC annual meetings. He has also served as a member on several working groups and review boards. Notably, he led the skin toxicities working group and served as a member of the gastrointestinal toxicity working group of the ASCO management of immune-mediated side effects guideline panel that developed the clinical practice guidelines on the management of immune-mediated side effects associated with immunotherapy. Dr. Naing is also a member of the SITC Immune Biomarkers Task Force, which functions with a goal of identifying the critical next steps in obtaining and handling biospecimens, biomarker identification, data and specimen sharing, and multi-disciplinary collaboration. He spearheaded MD Anderson’s collaborative effort with Project Ronin to develop a mobile app, which was launched recently to provide a ready-to-use look-up tool on management of immunotherapy-related toxicities. He is also the course director for Tumor Immunology course at the University of Texas Graduate School of Biomedical Sciences at Houston.

Ana I. Velázquez Mañana, MD, MSc
Assistant Professor, Division of Hematology Oncology, Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Ana I. Velázquez Mañana, MD, MSc

Dr. Ana Velázquez Mañana is a thoracic oncologist and Assistant Professor of Medicine in the University of California, San Francisco (UCSF) Division of Hematology/Oncology at Zuckerberg San Francisco General Hospital in California. As a Latina, she advocates for workforce diversity and gender equity and has been named the Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Training of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Velázquez completed her MD at the University of Puerto Rico School of Medicine, a Master of Biomedical Science at Mayo Clinic Graduate School of Biomedical Sciences (formerly known as Mayo Graduate School), and her Internal Medicine residency at Mount Sinai Beth Israel, where she was a Chief Resident. She joined UCSF in 2018, where she completed her clinical fellowship in Medical Oncology and postdoctoral research fellowship in the National Clinician Scholars Program.

Dr. Velázquez is a member of the prestigious John A. Watson Faculty Scholars Class of 2022 at UCSF and has been awarded a Conquer Cancer Foundation Young Investigator Award. She aims to support and improve the outcomes of patients with lung cancer from vulnerable backgrounds using health services and disparities research.

Statement of Need

People from racial and ethnic minority populations and those from under-resourced communities are more likely than non-Hispanic White people to encounter obstacles to cancer diagnosis and treatment. In particular, social determinants of health (SDoH) may restrict access to therapies, such as immune checkpoint inhibitors (ICIs). In addition, implicit and explicit biases may impact a patient’s receipt of guideline-recommended care. Strategies to integrate multilevel interventions are needed to provide equitable access to ICI therapy, reduce risk of adverse events, and optimize patient outcomes.

In this Webcast, expert faculty will discuss the treatment obstacles many patients from underserved communities face, especially for cancer therapies, such as ICIs. They will recommend practices clinicians can implement to help their patients overcome barriers to cancer therapies. Finally, faculty will help clinicians develop strategies to make changes on a personal level and within their practice, and suggest ways to break down structural inequities within their community to improve outcomes for their patients.

Learning Objectives

At the end of this CME/CE activity, participants should be able to develop strategies to reduce health disparities in patients experiencing irAE.

Financial Support

Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, nurse navigators, pharmacists, social workers, and case managers specializing in oncology, emergency medicine and/or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hour (0.075 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-22-103-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.Dr. Cook reports no financial relationships.

Dr. Naing reports the following financial relationships: Research Support: Amplimmune, Inc.; Arcus Biosciences, Inc.; ARMO BioSciences, Inc.; Atterocor, Inc.; Baxalta (I); Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Chao Physician-Scientist Awards (I), Baylor College of Medicine; CytomX Therapeutics, Inc.; EMD Serono Inc.; Healios Oncology Nutrition, LLC; Immune Deficiency Foundation (I); ImmuneOncia Therapeutics, Inc.; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; MedImmune; Lilly; Merck & Co., Inc.; Neon Therapeutics; NeoImmuneTech; National Cancer Institute (NCI); Novartis; Pfizer Inc.; PsiOxus Therapeutics; Regeneron Pharmaceuticals In; Surface Oncology; and TopAlliance BioSciences Inc. Other Financial or Material Support: (Travel, accommodations, expenses) ARMO Biosciences, Inc.

Dr. Velázquez Mañana reports the following financial relationships: Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc. Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • David Modrak, PhD (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Thomas Mitchell (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.


Action Steps to Address Inequities in Cancer Care Access, Treatment, and Outcomes in Your Community
Event Date: 08/15/2022 at 8:00 am